Researchers develop new drugs for treating polycystic hepatorena

May 11, 2020

Polycystic hepatorenal diseases are hereditary, genetic disorders characterised by the progressive development of multiple symptomatic cysts in the kidneys and/or liver which may cause alterations in the function of these organs and/or complications associated with their growth. Right now, there are no effective pharmacological treatments and the only curative option is organ transplant.

Researchers at the University of the Basque Country (UPV/EHU) led by Dr Fernando Cossío, scientific director of Ikerbasque, and in the Liver Diseases Group at the Biodonostia Institute of Health Research, led by the Ikerbasque research fellow Dr Jesús M. Bañales, have collaborated on the development of new drugs that have proven to be effective in reducing the growth of hepatic and renal cysts in experimental models of this disease, which could be of huge clinical significance. Researchers at the University of Salamanca, led by Dr José J. G. Marín, at the Idibell Institute of Catalonia, led by Dr Manel Esteller, and at the Hormel Institute of Minnesota (USA), headed by Dr Sergio Gradilone, have collaborated in this multidisciplinary project led by the two Basque institutions.

The drugs developed are based on the structure of ursodeoxycholic acid (UDCA), a bile acid present in the body at a low concentration and which has protective properties for the liver. In fact, its administration is recommended for treating specific liver diseases. The researchers based themselves on the structure and properties of this molecule to design and synthesise a family of chemical derivatives geared towards inhibiting a key protein responsible for encouraging the growth of hepatorenal cysts. The results published have shown that these new drugs are capable of blocking the growth of hepatic and renal cysts in an animal model of this disease.

The promising therapeutic effects of these new drugs have managed to spark great interest in the international scientific community. So much so that the work was selected to be presented orally at the International Congress of the EASL, the European Association for the Study of the Liver, held in Vienna. It has also been published recently in the prestigious international journal Hepatology (official journal of the American Association for the Study of Liver Diseases), and has given rise to the PhD thesis by Dr Francisco J. Caballero (UPV/EHU, Biodonostia), lead author of the said work, supervised by Dr Fernando Cossío (UPV/EHU) and Dr Jesús M. Bañales (Biodonostia, Ikerbasque).

This project recently received the FIPSE national award for Innovation (Ministry of Science and Innovation) which enabled a patent for these drugs to be taken out; they have been licensed to the company ATLAS Molecular Pharma of the Basque Country so that their clinical study can be pursued. This project has also had competitive funding from the RIS3 Euskadi Programme, Ministry of Science and Innovation, the Carlos III Institute of Health (ISCIII) and Ikerbasque.
-end-


University of the Basque Country

Related Innovation Articles from Brightsurf:

Food system innovation -- and how to get there
Food production has always shaped the lives of humans and the surface of the Earth.

What is the best way to encourage innovation? Competitive pay may be the answer
Economists and business leaders agree that innovation is a major force behind economic growth, but many disagree on what is the best way to encourage workers to produce the 'think-outside-of-the-box' ideas that create newer and better products and services.

Innovation is widespread in rural areas, not just cities
Conventional measures of innovation suggest that only big cities foster new ideas, but a more comprehensive measure developed at Penn State shows that innovation is widespread even in rural places not typically thought of as innovative.

Scaling up search for analogies could be key to innovation
Investment in research is at an all-time high, yet the rate of scientific breakthroughs isn't setting any records.

Why you should be concerned about Oprah Winfrey when introducing an innovation
New research by Bocconi University's Paola Cillo and Gaia Rubera with Texas A&M's David Griffith asserts that the reaction of large individual investors to innovation is an important component of stock returns, their reaction to innovation depends on their national culture, and there is a way to segment large individual investors and pitch innovation to them accordingly.

Responsible innovation key to smart farming
Responsible innovation that considers the wider impacts on society is key to smart farming, according to academics at the University of East Anglia (UEA).

Pillars of academic innovation
Highlights from the Sixth Annual Conference of the National Academy of Inventors, including high-tech solutions to combat child pornography and radicalization materials; groundbreaking programs to promote STEM major retention; and new materials for wearable technology.

Universities drive innovation in the classroom
The current issue of Technology and Innovation, Journal of the National Academy of Inventors ® (19.2) examines innovation from the university perspective, highlighting what the most innovative institutions and educators worldwide are doing to prepare future engineers and industry leaders to effectively manage IP to grow their companies and the global economy as a whole.

How universities are fostering innovation and entrepreneurship
Technology and Innovation 19.1 zeroes in on innovation and entrepreneurship, with a special focus on what universities are currently doing to foster growth in those areas both for their success and the success of the communities and regions to which they are connected.

Shaping the future of health innovation
Future advances in healthcare will be aided by a new £10 million facility -- the National Institute for Health Research Innovation Observatory based at Newcastle University, UK.

Read More: Innovation News and Innovation Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.